232 related articles for article (PubMed ID: 23006739)
1. The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
Zheng J; Zou X; Yao J
Chemotherapy; 2012; 58(4):273-81. PubMed ID: 23006739
[TBL] [Abstract][Full Text] [Related]
2. More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
Zheng J; Wang H; Yao J; Zou X
Pharmazie; 2014 Jan; 69(1):38-42. PubMed ID: 24601221
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
4. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
5. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
Roforth MM; Tan C
Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
8. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
[TBL] [Abstract][Full Text] [Related]
9. Embelin inhibits growth and induces apoptosis through the suppression of Akt/mTOR/S6K1 signaling cascades.
Kim SW; Kim SM; Bae H; Nam D; Lee JH; Lee SG; Shim BS; Kim SH; Ahn KS; Choi SH; Sethi G; Ahn KS
Prostate; 2013 Feb; 73(3):296-305. PubMed ID: 22887478
[TBL] [Abstract][Full Text] [Related]
10. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Cytokine; 2012 Oct; 60(1):38-42. PubMed ID: 22840496
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
12. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
Carraway H; Hidalgo M
Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
[TBL] [Abstract][Full Text] [Related]
13. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
[TBL] [Abstract][Full Text] [Related]
14. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
16. Involvement of PI3K-AKT-mTOR pathway in protein kinase CKII inhibition-mediated senescence in human colon cancer cells.
Park JH; Kim JJ; Bae YS
Biochem Biophys Res Commun; 2013 Apr; 433(4):420-5. PubMed ID: 23523798
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of a Fluorine-18 (
Altine B; Gai Y; Han N; Jiang Y; Ji H; Fang H; Niyonkuru A; Bakari KH; Rajab Arnous MM; Liu Q; Zhang Y; Lan X
Mol Pharm; 2019 Nov; 16(11):4563-4571. PubMed ID: 31553879
[TBL] [Abstract][Full Text] [Related]
18. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer.
Nozawa H; Watanabe T; Nagawa H
Cancer Lett; 2007 Jun; 251(1):105-13. PubMed ID: 17175097
[TBL] [Abstract][Full Text] [Related]
20. Determinants of rapamycin sensitivity in breast cancer cells.
Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F
Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]